- The FDA has placed a partial clinical hold on Blueprint Medicines Corporation’s BPMC Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients.
- Patients currently enrolled in the trial continue on the study drug, and additional patients will not be enrolled until the partial clinical hold is resolved.
- Also Read: Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake.
- The reported visual AEs consisted of transient, reversible episodes of light sensitivity and blurred vision.
- All events were Grade 1, except one Grade 3 event involving light sensitivity and blurred vision in a patient treated at 600 mg BID.
- All events were resolved with dose interruption or reduction.
- No treatment-emergent abnormal findings, including uveitis, have been observed in patients who have received detailed ophthalmologic examinations.
- Consistent with prior guidance, Blueprint Medicines plans to present initial dose escalation data from the VELA trial of BLU-222 in the first half of 2023.
- “We have confidence in the benefit-risk profile of BLU-222 based on the activity and safety data we have seen to date in the dose escalation study,” said Becker Hewes, Chief Medical Officer.
- Price Action: BPMC shares are down 7.88% at $40.80 during the premarket session on the last check Friday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
